Clinical response benefit in patients with advanced pancreatic cancer

Digestion

Volumn 58, Issue 6, 1997, Pages 503-507

  Carmichael, James ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Advanced pancreatic cancer; Clinical benefit response; Gemcitabine; Solid tumour

Indexed keywords

FLUOROURACIL; GEMCITABINE; NITROGEN; PYRIMIDINE ANTAGONIST;

ADVANCED CANCER; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; FATIGUE; FLU LIKE SYNDROME; HEMOLYTIC UREMIC SYNDROME; HUMAN; KIDNEY DISEASE; LIVER TOXICITY; NEUTROPENIA; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; THROMBOCYTOPENIA; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CLINICAL TRIALS; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 0030722875     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000201493     Document Type: Article

References (14)

1. Jensen OM, Esteve J, Möller H, Renard H: Cancer in the European Community and its Member Stales, Eur J Cancer 1990:51:6110-6117.
2. Brennan MF, Kinsella TJ, Casper ES: Cancer of the pancreas; in De Vita VT Jr, Heilman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, ed 4, Philadelphia, Lip-pincott, 1993, vol 3, pp 849-882.
3. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W: Action of 2'2'-difluorodeoxycyti-dine on DNA synthesis, Cancer Res 1991:51: 6110-6117.
4. Plunkett W, Gandhi V, Chubb S, Nowark B, et al: 2'2'-Difluorodeoxycylidine metabolism and mechanism of action in human leukaemia cells, Nucleosides Nucleotides 1989:8:775-785.
5. Xu Z-Y, Plunkett W: Modulation of dcoxycy-tidinc deaminase in intact human leukemia cells: Action of 2'2-difluorodeoxycytidine, Biochem Pharmacol 1992:44:1819-1827.
6. Heinemann V, Hertel L, Grindey GB, Plunkett W: Comparison of the cellular pharmacokinetics and toxicity of 2'2'-difluorodcoxycytidinc and l-b-D-arabinofuranosylcytosinc, Cancer Res 1988:48:4024-4031.
7. Hertel LW, Bodcr GB, Drain JS, Rinzel SM, Poore GA, Todd GC, Grindey GB: Evaluation of the antitumour activity of gcmcitabinc (2'2'-difluoro-2-dcoxycytidine), Cancer Res 1990: 50:4417-4422.
8. Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH: Singlec agent activity of weekly gemcitabine in advanced non-small cell lung cancer: A phase II study, J Clin Oncol 1994:12:1821-1826.
9. Lund B, Hansen OP, Thciladc K, Hasen M, Ncijt JP: Phase II study of gemcitabine (22-difluorodeoxycytidine) in previously treated ovarian cancer, J Natl Cancer Inst 1994:86: 1530-1533.
10. Carmichael J, Possinger K, Philip P, Beylarch M, Kerr H, Walling J, Harris AL: Dilluoro-deoxycytidine (gemeitabine): A phase II study in patients with advanced breast cancer (abstr 57), Proc Am Soe Clin Oncol 1993; 12:64.
11. Casper SE, Green MR, Kelsen DP, et al: Phase II trial of gemcitabine (2'2'-difluorodeoxycy-tidine) in patients with adenocarcinoma of the pancreas, New Drugs 1994:12:29-34.
12. Carmichael J, Fink UI, Russell RCG, Spittle ME, Harris AL, Spiessl G, Blatter J: Phase II study of gemcitabine in patients with advanced pancreatic cancer, Br J Cancer 1996:73:101-105.
13. Burris HA, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer, J Clin Oncol 1997:15:2403-2413.
14. Moore M: Improvements in survival and clinical benefit with the use of gemcitabine as first line therapy for advanced pancreatic cancer: A randomised trial, Eur J Cancer 1995:31A (suppl 5):54.